Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.03
$0.06
$0.00
$0.78
$1.42M1.175,440 shs95 shs
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
$11.04
-6.0%
$14.01
$7.05
$17.15
$308.18M0.3758,648 shs98,440 shs
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
$0.30
-25.9%
$0.36
$0.30
$1.34
$1.02M1.8289,627 shs753,013 shs
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$2.13
-1.4%
$2.21
$1.62
$14.67
$5.12M0.98955,109 shs76,623 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%-77.38%-72.32%+5.21%-77.80%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-5.96%-13.62%-26.10%-19.71%+13.81%
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
0.00%0.00%0.00%0.00%-78.42%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-1.39%-1.39%0.00%+21.02%-69.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
1.9103 of 5 stars
3.61.00.00.03.40.80.0
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.4631 of 5 stars
0.04.00.00.01.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
3.20
Buy$23.83115.88% Upside
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
0.00
N/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BNTC, CYTO, ENSC, and ADXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/19/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/15/2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M0.44N/AN/A($2.06) per share-0.02
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/A$4.68 per shareN/A
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
$320K3.19N/AN/A$4.56 per share0.07
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.21M0.97N/AN/A$2.59 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
-$4.31MN/A0.00N/AN/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)

Latest BNTC, CYTO, ENSC, and ADXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$1.02N/AN/AN/A$0.67 millionN/A
5/14/2025Q3 2025
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
-$0.36-$0.24+$0.12-$0.24N/AN/A
5/13/2025Q1 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
N/AN/AN/AN/AN/A
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
0.01
14.80
14.80
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
N/A
0.43
N/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
2.50
2.50

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
52.19%
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
1.91%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
5.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2042.63 million42.36 millionNot Optionable
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
2026.25 million25.91 millionNo Data
Altamira Therapeutics Ltd. stock logo
CYTO
Altamira Therapeutics
203.40 million2.96 millionNot Optionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
102.37 million2.18 millionNot Optionable

Recent News About These Companies

ENSC Start Phase 3 Trial on Abuse-Resistant Pain Reliever
Ensysce Flat on Receiving Grant
Ensysce Biosciences secures patent for OUD treatment
Ensysce Biosciences receives U.S. patent for OUD treatment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.03 0.00 (0.00%)
As of 07/18/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Benitec Biopharma stock logo

Benitec Biopharma NASDAQ:BNTC

$11.04 -0.70 (-5.96%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$11.06 +0.02 (+0.14%)
As of 07/18/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Altamira Therapeutics stock logo

Altamira Therapeutics NASDAQ:CYTO

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$2.13 -0.03 (-1.39%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.12 -0.01 (-0.47%)
As of 07/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.